Biotech firm receives $24M to develop neurorestorative therapies

A Boston-area biotech company has received $24 million in Series A funding to develop neurorestorative and remyelinating therapies for a broad range of neurological conditions.
According to a release from Myrobalan Therapeutics, the financing, which comes from various investors, will be applied to advancing an antagonist to G-protein coupled receptor 17; a central target to promote remyelination; an inhibitor to colony-stimulating factor-1 receptor involved in both demyelination and neuroinflammation; and an allosteric tyrosine kinase 2 (TYK2) inhibitor that reduces neuroinflammation.
The goal

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart